Attached files
| file | filename |
|---|---|
| EX-99.1 - NEXIEN BIOPHARMA, INC. | ex99-1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of report (date of earliest event reported): February 5, 2018
Intiva
BioPharma Inc.
(Exact Name Of Registrant As Specified In Its Charter)
Commission File No.: 000-55320
| Delaware | 26-2049376 | |
| (State of Incorporation) | (I.R.S. Employer Identification No.) | |
| 4340 East Kentucky Avenue, Suite 206, Glendale, CO 80246 | 80246 | |
| (Address of Principal Executive Offices) | (ZIP Code) |
Registrant’s Telephone Number, including area code: (303) 495-7583
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| [ ] | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| [ ] | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| [ ] | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| [ ] | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
[X] Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.
[ ] If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 8.01. Other Events.
Intiva BioPharma Inc. (the “Registrant”) is reporting the publication on February 5, 2018, of the attached press release announcing the Registrant’s response to the actions of U.S. Attorney General Jeff Sessions and the Department of Justice dated January 4, 2018 and the fact that such actions will not adversely impact the Registrant’s operations or business plans.
Reference is made to the full text of the press release filed as Exhibit 99.1 herewith.
Item 9.01 Financial Statements and Exhibits.
(a) The following documents are filed as exhibits to this report on Form 8-K or incorporated by reference herein. Any document incorporated by reference is identified by a parenthetical reference to the SEC filing that included such document.
Exhibits
(a) The following documents are filed as exhibits to this report on Form 8-K or incorporated by reference herein. Any document incorporated by reference is identified by a parenthetical reference to the SEC filing that included such document.
| Exhibit No. | Description | |
| 99.1 | Press Release dated February 5, 2018, filed herewith. |
Signatures
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| /s/: Jeffrey Friedland | |
| Jeffrey Friedland, CEO | |
| Dated: February 5, 2018 |